tem stock: Tempus AI (TEM) Guide

TEM (Tempus AI, Inc.)

Quick summary: Tempus AI, traded under the ticker tem stock (NASDAQ: TEM), is a U.S.-based healthcare technology company that applies artificial intelligence and large-scale clinical and molecular data to precision medicine, diagnostics, and drug development. This article explains the company's background, products, markets, financial posture, regulatory context, and recent news to help readers understand tem stock and where to find authoritative disclosures.

Company overview

Tempus AI was founded in 2015 by entrepreneur Eric Lefkofsky and is headquartered in Chicago, Illinois. The company’s stated mission is to bring AI and machine learning (AI/ML) into clinical care at scale by combining clinical, molecular and real‑world data with analytic and decision‑support tools.

Tempus operates a multi‑disciplinary corporate structure that spans genomics laboratories, clinical services, research partnerships, and software engineering. As a large health‑tech organization, the company employs thousands of staff across laboratory operations, clinical teams, data science, engineering, sales and administrative functions. tem stock investors and analysts typically track employee count and operational scale as indicators of the company’s ability to execute on laboratory throughput and data generation.

Why this matters: Tempus’s value proposition depends on proprietary data scale, validated assays, and commercial agreements with health systems and biopharma. tem stock reflects investor expectations about growth in those areas.

Ticker and market listing

• Stock symbol: TEM (commonly referenced as tem stock in market commentary)
• Exchange: NASDAQ
• ISIN: US88023B1035
• IPO: Tempus completed its initial public offering with an IPO date recorded as June 14, 2024. The formal offering documentation and registration statements filed with the SEC record the offer details; readers should consult those filings for the exact offer price and underwriting information.
• Trading hours: As a NASDAQ‑listed equity, TEM trades during standard U.S. equity market hours (normally 9:30 a.m. to 4:00 p.m. Eastern Time, with pre‑market and after‑hours sessions subject to broker and market rules).

Trading characteristics: tem stock has attracted active trading interest since its public listing, including notable short interest and institutional holdings referenced in market data coverage. As of January 2026 market reports, intraday price levels and volume spikes can reflect news flow about clinical validation, partnerships, and macro healthcare themes.

History and corporate milestones

Tempus’s development path includes research and commercial milestones that underpin tem stock’s narrative.

• Founding (2015): Eric Lefkofsky founded Tempus to aggregate clinical and molecular data and apply machine learning to clinical decision support and drug development.

• Laboratory and product buildout: Over several years Tempus invested in CLIA‑certified laboratories, next‑generation sequencing capacity, and bioinformatics pipelines, enabling broad oncology genomic profiling and clinical reporting.

• Strategic integrations and acquisitions: Tempus has grown not only organically but also through acquisitions and integrations to expand its testing menu and data assets. Public filings and coverage reference transactions such as the integration of Ambry Genetics assets and capabilities (referenced in company filings and press coverage). Such integrations broaden Tempus’s diagnostic offerings and sample volume.

• Commercial partnerships: Tempus established collaborations with health systems, academic centers, and biopharma companies to supply genomic testing, data licensing, and AI tools for trial matching and biomarker discovery.

• Regulatory and validation milestones: The company has pursued clinical validation and regulatory clearances for certain algorithms and tests, and has published validation data for components of its diagnostic and decision‑support portfolio.

• IPO (June 14, 2024): The company became publicly listed, enabling wider institutional ownership and increased market scrutiny of its commercial and financial trajectory.

These milestones combine operational scale (labs and data), technology offers (AI/ML tools), and commercial traction — all core inputs to tem stock’s market story.

Business model and products

Tempus’s business model rests on three interrelated pillars: genomic and diagnostic testing, data licensing and AI applications, and adjacent services sold to healthcare and life‑science customers.

Genomics and Diagnostics

Tempus provides genomic testing services primarily focused on oncology, including broad genomic profiling (tumor sequencing), targeted panels, and companion diagnostic workflows. These services are delivered from CLIA/CAP‑compliant labs and are designed to inform therapy selection, clinical trial matching, and clinical reporting.

Key points:

• Oncology assays: Tempus offers oncology sequencing assays that detect somatic mutations, copy number changes, and other genomic alterations relevant to targeted therapies and immunotherapy decisions.
• Companion diagnostics (CDx) and biomarker testing: Where applicable, the company develops tests and reporting workflows intended to support therapy selection and enrollment in trials; some tests may be developed as companion diagnostics in collaboration with drug developers.
• Turnaround and integration: Lab scale and automation affect turnaround time, a commercial differentiator for providers and health systems that must deliver timely test results.

Data licensing and AI applications

A central asset for Tempus is its large, linked dataset that pairs clinical records with molecular and genomic data. The company packages data and analytic insights as products for life sciences customers and clinical partners.

Product categories:

• Data licensing: Aggregated and de‑identified data sets, cohort analytics, and curated clinical‑molecular datasets licensed to pharmaceutical companies and researchers for biomarker discovery, trial design and post‑market evidence generation.
• AI/ML tools: Software tools that apply machine learning to pathology slides (digital pathology), imaging, and clinical data to provide decision support. Coverage references digital pathology initiatives and algorithmic products such as an ECG‑based atrial fibrillation (AF) detection algorithm (ECG‑AF) as examples of algorithmic applications.
• Clinical decision support: Integrated systems and clinical workflows that surface genomic insights to clinicians, aid in trial matching, and assist care teams in identifying therapy options.

These offerings position Tempus as more than a testing lab: the company markets itself as a data‑and‑AI platform that enables both point‑of‑care decisions and the drug‑development pipeline.

Revenue streams and customers

Tempus generates revenue primarily through three channels:

• Clinical testing revenue: Fees from genomic and diagnostic tests ordered by clinicians or health systems.
• Biopharma and research revenue: Contract revenue from pharmaceutical and biotechnology companies for data licensing, assay development, clinical trial support and biomarker services.
• Software and services: Subscription or service fees for AI/ML tools, decision‑support software, and managed data‑analysis engagements.

Primary customers include health systems, oncology practices, commercial laboratories, pharmaceutical companies, and research institutions. Contract backlog, multi‑year agreements, and commercial partnerships are common in discussions of tem stock because they signal recurring revenue potential and longer‑term revenue visibility.

How revenue is generated across segments:

• Genomics/diagnostics: Fee‑for‑service testing (volume‑driven).
• Data services: Contracted data licensing, cohort creation, and research consulting fees.
• Software: Platform access fees and partnership revenue tied to implementation.

Revenue mix and margins vary by segment: lab services can entail lower gross margin due to reagent and processing costs, whereas data licensing and software typically carry higher gross margins once infrastructure is in place.

Financial performance and key metrics

This section summarizes the types of financial metrics investors examine in tem stock coverage and highlights the channels where numerical detail is typically reported. Readers are encouraged to consult Tempus’s SEC filings for the latest audited figures.

Historical financials

• Revenue growth: Public commentary and filings highlight multi‑year revenue growth as the company scales testing volume and expands data and pharma contracts. tem stock performance is sensitive to reported revenue growth rates and quarterly trends.
• Profitability: Like many growth‑stage healthcare technology companies, Tempus has reported net losses as it invests heavily in labs, R&D and commercial expansion. Gross margin trends depend on test mix (higher‑margin data licensing vs. lower‑margin lab services).
• Trailing metrics: Analysts and platforms report trailing twelve‑month (TTM) revenue and adjusted operating metrics; these are used to calculate growth multiples and gross margin trends.

As of the company’s latest periodic filings, detailed numeric values for revenue, net loss, and gross margin are disclosed in the Form 10‑Q and Form 10‑K. tem stock commentators often cite those trailing metrics when discussing valuation and runway.

Guidance and analyst expectations

Management guidance and sell‑side analyst models often focus on multi‑year revenue targets, adjusted EBITDA milestones, and operating leverage as Tempus transitions parts of the business toward higher‑margin data licensing.

• Example coverage: Analyst writeups (e.g., Seeking Alpha summaries) have referenced multi‑year guidance scenarios and EBITDA targets for 2026; these should be read alongside management’s public guidance.
• Valuation metrics: Given negative or variable earnings, common valuation approaches include enterprise‑value‑to‑revenue multiples and revenue growth comparables. tem stock may trade at premiums or discounts depending on growth expectations and proof points such as FDA clearances, large pharma deals, or durability of lab margins.

Balance sheet and cash flow considerations

Key balance‑sheet items for tem stock watchers include the company’s cash position, available liquidity, debt or lease obligations, and operating cash flow trends.

• Cash runway: For growth companies implementing capital‑intensive lab operations, monitoring cash burn and financing activity (equity raises, convertible notes, credit facilities) is central to evaluating capital needs.
• Debt and leverage: The company’s filings disclose any outstanding borrowings and lease liabilities.

Readers should consult the most recent Form 10‑Q / 10‑K for up‑to‑date balance sheet and cash‑flow numbers; tem stock investors use those filings to assess whether the company has sufficient resources to execute its growth plans.

Stock performance and market data

This section compiles market data points commonly cited in coverage of tem stock. Quoted figures below are drawn from market reporting and public market data snapshots; for real‑time data consult your market data provider or exchange.

Price history and trading statistics

• Representative price snapshots: In market summaries, TEM has been quoted in ranges around mid‑$60s per share in recent market snapshots (for example, market feeds showed tem stock at roughly $65.50 and $66.32 in January 2026 summaries). These values are illustrative of price levels reported in market coverage during that period.
• Short interest: As of January 2026 market reporting, short interest in Tempus had risen — exchange‑reported data showed approximately 20.07 million shares sold short, representing roughly 15.64% of the tradable float, with an estimated 5.11 days to cover based on recent volume figures (source: Benzinga automated market summary). This elevated short interest is a signal of heightened bearish positioning among some traders but does not by itself predict future price moves.
• Volume and volatility: tem stock has shown periods of elevated average daily volume and intraday swings tied to news events such as clinical results, regulatory updates, partnerships, and broader sector moves.
• Shares outstanding/float & market cap: These figures are periodically updated in company disclosures and market data pages. For the most up‑to‑date share counts, market cap and float, consult the company’s investor relations materials or major market data providers.

Analyst coverage and ratings

A range of sell‑side analysts and independent research outlets cover tem stock. Analyst sentiment commonly includes buy/hold/sell ratings, target price ranges, and commentary focused on growth, margin improvement, and the path to profitability. Readers should review multiple sources and the dates of coverage when gauging consensus.

Notable investors and institutional ownership

Institutional ownership can materially influence tem stock’s liquidity and forward trading dynamics.

• Reported allocators: Coverage in major news summaries has noted thematic investors and ETFs that include Tempus — for example, Ark Invest named Tempus among companies tied to the “Multiomics” theme in its Big Ideas 2026 report, highlighting Tempus as an example of firms positioned at the intersection of AI and genomics (see below for dated reference).
• Institutional holdings: Major mutual funds, ETFs and asset managers are typically listed among top holders on market pages; these positions are updated in quarterly 13F filings and market data snapshots.

Partnerships, collaborations and customers

Tempus’s commercial strategy emphasizes partnerships across health systems and biopharma to scale test volume and build data assets.

• Pharma collaborations: Tempus licenses data and analytic services to pharmaceutical companies for biomarker discovery, trial enrichment, and companion test development. These collaborations can include co‑development of assays or custom data feeds.
• Health system integrations: Partnerships with large health systems support clinical adoption of Tempus tests and tie patient outcomes to molecular data, which in turn fuels the company’s data asset.
• Research collaborations: Academic and research institutions may access Tempus datasets for discovery studies, while Tempus benefits from co‑authored publications and clinical validation data.

Partnerships matter for tem stock because multi‑year contracts and pilot‑to‑enterprise conversions create recurring revenue opportunities and improve the company’s addressable data footprint.

Regulatory, legal and compliance matters

Given the clinical nature of its products, Tempus operates in a highly regulated environment.

Regulatory clearances and clinical validation

• FDA and other clearances: Some of Tempus’s tests and algorithms are subject to regulatory pathways and clinical validation requirements. The company has pursued validation and, where applicable, regulatory submission or clearance for specific algorithms and tests. Readers should review recent press releases and SEC filings for the current status of any FDA submissions or clearances relating to algorithms or diagnostic assays.
• Clinical validation: Tempus frequently publishes validation data for assays and algorithms, a key consideration for adoption by clinicians and health systems.

SEC filings and disclosures

• Periodic reporting: Tempus’s SEC filings (Form 10‑K annual reports and Form 10‑Q quarterly reports) provide comprehensive disclosure on risk factors, revenue recognition policies, contractual obligations, litigation and governance. tem stock commentary routinely references these filings for authoritative detail.
• Risk factors: The company’s periodic reports list principal risks, including regulatory and reimbursement uncertainty, operational dependencies, and data security/privacy risks.

Recent developments and news highlights

Below are representative items reported in major outlets and market summaries that have influenced tem stock sentiment. All items are time‑stamped in coverage where noted.

• Ark Invest inclusion (January 2026): As of January 2026, Ark Invest included Tempus AI among companies cited for the Multiomics theme in its Big Ideas 2026 report, highlighting the role of AI‑native biology and multiomics in healthcare advances. This thematic endorsement is notable because it places tem stock among companies that thematic investors may track for exposure to genomic and AI healthcare innovation (Source: Ark Invest Big Ideas 2026 report).

• Short interest rise (January 2026): As reported by market data summaries, short interest in Tempus increased to approximately 20.07 million shares (about 15.64% of float) with an estimated 5.11 days to cover, signaling that a non‑trivial share of the tradable market had a bearish position (Source: Benzinga automated market summary). As of that reporting period, the short interest uptick was a commonly‑cited market dynamic for tem stock.

• Conference presentations and clinical data: Tempus management and scientific teams have presented at major healthcare conferences (including high‑profile investor and healthcare meetings). These presentations often highlight assay performance, commercial wins, and research collaborations and can move tem stock on data updates.

• Integrations and commercial contracts: Press coverage and filings have referenced the integration of Ambry Genetics capabilities and other commercial contract announcements that expand Tempus’s test menu and data intake. Such items are material to tem stock narratives because they influence revenue mix and data scale.

For the latest developments, always check the company’s investor relations releases and the most recent SEC filings. This article reflects reporting available up to early 2026; readers should note dates for each cited item.

Risks and controversies

The principal business risks for Tempus — frequently listed in SEC filings and analyst coverage — include:

• Regulatory and reimbursement risk: Diagnostic tests and AI algorithms face regulatory scrutiny and evolving reimbursement policies from payors that affect adoption and revenue realization.
• Competition: The genomics, diagnostics and healthcare AI markets include established players and new entrants. Competitive pressure can impact pricing, commercial share and margin.
• Data privacy and security: Handling sensitive clinical and genomic data requires robust compliance with HIPAA and other data‑protection frameworks; breaches or compliance failures would be material.
• Dependence on partners and payors: Revenue concentration with a small set of large customers or delays in payor coverage decisions can affect near‑term cash flow.
• Path to profitability: High upfront capital intensity for labs and R&D means the company’s ability to scale higher‑margin data licensing and software revenue is critical to long‑term profitability.

These risks are covered in the company’s periodic reports; tem stock commentary typically revisits them after major regulatory, commercial or financial announcements.

Corporate governance and management

• Leadership: Eric Lefkofsky, the company’s founder, has served in senior leadership roles and is often cited as CEO and a principal executive in filings and press coverage. Other named executives include heads of labs, chief medical officers, and heads of data science and commercial operations.
• Board and governance: The company’s Board composition and governance policies are disclosed in proxy statements and the Form 10‑K. Governance provisions, board committee charters, and related party disclosures are available in those filings.

Good governance and experienced management teams are factors often discussed when evaluating tem stock, particularly in how they balance commercialization vs. research priorities.

See also

• Precision medicine
• Genomic diagnostics
• Healthcare AI and machine learning
• Multiomics and biomarker discovery
• Competitors and peers in health‑tech and diagnostics (consult SEC filings and industry analyses for peer lists)

References and further reading

For authoritative information on tem stock, consult these primary sources and reputable market coverage. (Dates indicate reporting context where applicable.)

• Company SEC filings (Form 10‑K, Form 10‑Q, registration statements) — for audited financials, risk factors, share counts and offering details.
• Ark Invest, Big Ideas 2026 report — As of January 2026, Ark Invest included Tempus AI in its Multiomics theme coverage (Ark Invest Big Ideas 2026).
• Market data summaries (Benzinga automated market content and market data snapshots) — short interest, price snapshots and trading statistics were cited in January 2026 market summaries.
• Major financial news outlets and analyst write‑ups (e.g., Seeking Alpha, Motley Fool summaries) — for analyst commentary and model scenarios.
• Nasdaq and major market data providers — for real‑time price, float and shares outstanding updates.

All readers should verify numerical figures and up‑to‑date developments directly from primary sources (company filings and investor relations announcements). This article provides a structured guide to tem stock topics but does not constitute financial advice.

Further exploration and next steps

If you want to follow tem stock further:

• Review the latest Form 10‑Q / 10‑K and investor presentations on Tempus’s investor relations site for audited numbers and management commentary.
• Track major healthcare conferences where Tempus presents to follow new clinical validation data and product announcements.
• Monitor market data for short interest and volume changes; elevated short interest can be informative about market positioning but should be interpreted with context.

Explore trading and research tools on Bitget to monitor tem stock price action and set up alerts. For custody and wallet needs tied to web3 assets, consider Bitget Wallet for secure management of on‑chain holdings.

Further reading and regular monitoring will help keep tem stock context current as new data, regulatory steps and commercial contracts are announced.

Note on sources and dates: This article references materials and market snapshots current through January 2026 (for example, Ark Invest’s Big Ideas 2026 report and Benzinga market summaries). For any numerical detail, please consult the primary SEC filings and the most recent market data feeds to confirm up‑to‑date values.

Explore more: discover tem stock filings and recent press releases on the Tempus investor relations page, and track market data via Bitget market tools.